Cell Culture Market Size
The global cell culture market size was estimated at USD 19.13 billion in 2025 and is projected to reach USD 50.54 billion by 2033, growing at a CAGR of 12.94% from 2026 to 2033.
It is a major technique used in both molecular and cellular biology as it provides the best platform for studying the normal physiology and biochemistry of cells. This process is significantly important in vaccine development, screening, and diagnosis of a given disease/condition.
Cell Culture Market Summary
| Metrics | Details |
| Market CAGR | 12.94% |
| Segments Covered | By Product, By End User, By Application, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Download free sample click here
Cell Culture Market Trends
The global cell culture market growth is driven by the increase in the number of cancer research projects using cell culture, extensive usage of gene therapies, recent developments in novel vaccine therapies, growing usage, and diverse application of stem cells.
The increasing contact between humans and animals will drive the market growth
The cell culture technology has been used to produce vaccines for rotavirus, polio, smallpox, hepatitis, rubella, and chickenpox. Cell-based flu vaccines have also been approved for use in the US and many European countries. Increasing awareness of the benefits of cell culture-based vaccines, coupled with the regulatory approval of several cell culture-based vaccines worldwide, are the major factors in the growth of the cell culture market during the forecast period.
The companies are also investing in the research and development of new technologies. Belgium Based CDMO Univercells received up to EUR 50 million in financings from Gamma Biosciences, a new investment platform supported by a leading global investment firm, KKR, focused on next-generation bioprocessing technologies for the production of advanced biologic therapies, including gene- and cell-based therapies.
The high cost of cell biology research will hamper the growth of the market
Cell biology involves extensive R&D on new therapies such as stem cell and gene therapies. The equipment, reagents, and other products associated with research must be of the highest quality to provide accurate results. Owing to the growing need to maintain high-quality standards (through the use of high-grade products) and comply with guidelines set up by regulatory bodies, the cost of cell biology research has increased considerably. As a result, various academic institutes and small-scale companies with limited budgets cannot afford to conduct cell biology research. This factor will hamper the growth of the market in the forecast period.
Cell Culture Market Segmentation Analysis
The drug screening & development segment is expected to grow at the fastest CAGR during the forecast period (2024-2031).
Cell culture is an integral part of medical research and drug discovery. The two-dimensional (2D) culture has been the preferred method for many decades due to the ease with which cell monolayers can be induced to proliferate on planar surfaces. The cell culture industry has witnessed its evolution, and currently, there has been an emergence of 3D cell culture in the market. Drug development is a time-consuming and costly procedure that is finished in multiple stages, from target identification to lead discovery and optimization, preclinical validation, and clinical trials culminating in approval for clinical use. Cell-based high throughput screening (HTS) is currently being carried out on cultured cells propagated in two dimensions (2D) on plastic surfaces optimized for tissue culture. With the emergence of 3D cell culture, the process of HTS has become easier and more accurate.
Furthermore, various global regulatory groups have improved their support for gene and cell therapy, which is positive. There was a notion of an "arms race" between different regional bodies the United States, Europe, the United Kingdom, China, and Japan to a degree, and in various ways within different specialties. Recently, it appears that regulatory authorities have been more open and collaborative in recognizing the differences between cell and gene therapy and more established biopharma cancer treatments. They are willing to put in place the necessary regulatory mechanism to allow these drugs to reach the market and to monitor them in the future. Thus, these factors are driving the growth of the market in the forecast period.
Cell Culture Market Geographical Share
North America region holds the largest market share of the global cell culture market
North America dominates the market for cell culture market owing to the growing demand for personalized medicine and the presence of key players in the market. Additionally, the United States government is supportive in terms of medical research as healthcare is one of the major priorities in the country. The initiative included the US National Cancer Institute (NCI) in Bethesda, Maryland, Cancer Research UK, the Welcome Trust Sanger Institute UK, and Hubrecht Organoid Technology of Utrecht in the Netherlands.
Fetal bovine serum (FBS) is the most widely used growth supplement for cell culture because it cost-effectively supports the survival and growth of many cell lines. However, the FDA has put several requirements in place for the production process due to the risk of contamination. With the rising focus on cell-based research, it is believed that there may be more technological advancements in the field, and this is likely to impact the US market in a positive manner in the forecast period.
Cell Culture Companies and Competitive Landscape
The cell culture market is a moderately competitive presence of local as well as global companies. Some of the key players that are contributing to the growth of the market include Biospherix, Hi-Media Laboratories, Merck KgaA, Promocell GmbH, Sartorius AG, Thermo Fisher Scientific, Danaher Corporation, Sekisui XenoTech LLC, Lonza Group, Agilent Technologies Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the cell culture market globally.
Bayer AG
Overview:
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Product Portfolio:
Roller Bottles and Accessories: Thermo Scientific Nunc PETG Roller Bottles are molded in shatter-resistant PETG and are available on both smooth and pleated surfaces. Growth areas range from 1,050 cm² to 4,200 cm² help enable increased cell expansion and product yield without investing in additional equipment or increased labor. PETG can be frozen to –40°C for freeze-thaw release protocols.
Recent Development:-
June 2025: Celltrio secured USD 15 million in funding led by Premier Partners to accelerate the global commercialization of RoboCell, its automated platform for sterile cell culturing and cell therapy manufacturing, indicating continued investor interest in cell-culture automation and cell-therapy workflows.
May 2025: The Maryland Stem Cell Research Commission announced more than USD 18 million in grants to support stem cell and regenerative medicine research, reinforcing the funding tailwind behind cell-based research demand in the cell culture market.
May 2025: BD launched the BD FACSDiscover A8 Cell Analyzer, which combines spectral and real-time cell imaging technologies, adding advanced analytical capability for cell-culture and cell-analysis workflows.
